BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38260161)

  • 21. Comparative histopathological analysis of sporadic pediatric papillary thyroid carcinoma from Japan and Ukraine.
    Bogdanova TI; Saenko VA; Hirokawa M; Ito M; Zurnadzhy LY; Hayashi T; Rogounovitch TI; Miyauchi A; Tronko MD; Yamashita S
    Endocr J; 2017 Oct; 64(10):977-993. PubMed ID: 28794343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk Haplotypes Uniquely Associated with Radioiodine-Refractory Thyroid Cancer Patients of High African Ancestry.
    Hurst Z; Liyanarachchi S; He H; Brock P; Sipos J; Nabhan F; Kebebew E; Green P; Cote GJ; Sherman S; Walker CJ; Chang YS; Xue S; Hollingsworth B; Li W; Genutis L; Menq E; de la Chapelle A; Jhiang SM
    Thyroid; 2019 Apr; 29(4):530-539. PubMed ID: 30654714
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Outcomes of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers.
    Toro-Tobon D; Morris JC; Hilger C; Peskey C; Durski JM; Ryder M
    Thyroid; 2024 Jan; 34(1):70-81. PubMed ID: 37917101
    [No Abstract]   [Full Text] [Related]  

  • 24. Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.
    Li J; Liang J; Zhao T; Lin Y
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1034-9. PubMed ID: 26780618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term clinical outcomes and prognostic factors for patients with papillary thyroid carcinoma with other organ invasions after adjuvant radioactive iodine.
    Kawamoto T; Shikama N; Fukumori T; Hoshi M; Yamada T
    Endocrine; 2023 Apr; 80(1):79-85. PubMed ID: 36367673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Morphologic characteristics of Chernobyl-related childhood papillary thyroid carcinomas are independent of radiation exposure but vary with iodine intake.
    Williams ED; Abrosimov A; Bogdanova T; Demidchik EP; Ito M; LiVolsi V; Lushnikov E; Rosai J; Tronko MD; Tsyb AF; Vowler SL; Thomas GA
    Thyroid; 2008 Aug; 18(8):847-52. PubMed ID: 18651805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radioactive iodine (RAI) therapy for distantly metastatic differentiated thyroid cancer (DTC) in juvenile versus adult patients.
    Kammori M; Fukumori T; Sugishita Y; Hoshi M; Shimizu K; Yamada T
    Endocr J; 2015; 62(12):1067-75. PubMed ID: 26424174
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radioactive iodine ablation does not prevent recurrences in patients with papillary thyroid microcarcinoma.
    Kim HJ; Kim NK; Choi JH; Kim SW; Jin SM; Suh S; Bae JC; Min YK; Chung JH; Kim SW
    Clin Endocrinol (Oxf); 2013 Apr; 78(4):614-20. PubMed ID: 22957654
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma.
    Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
    Endocr Relat Cancer; 2016 May; 23(5):367-76. PubMed ID: 26917553
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PD-L1 and MCL-1 markers and the relationship with prognostic characteristics of differentiated thyroid carcinoma.
    Zantut-Wittmann DE; Barreto IS; Laus AC; Moreno DA; Moma CA; Maia FFR; Assumpção LVMD; Reis RM
    Mol Cell Endocrinol; 2023 Jun; 570():111931. PubMed ID: 37072108
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical outcomes and risk stratification for papillary thyroid carcinoma presenting with distant metastasis before the era of tyrosine kinase inhibitors.
    Matsuzu K; Sugino K; Masudo K; Mori K; Ono R; Yamazaki H; Masaki C; Akaishi J; Kiyomi Yamada H; Tomoda C; Suzuki A; Uruno T; Ohkuwa K; Kitagawa W; Nagahama M; Takami H; Ito K
    Endocr J; 2020 Aug; 67(8):869-876. PubMed ID: 32350192
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Microscopic positive margins in papillary thyroid cancer do not impact disease recurrence.
    Abraham E; Tran B; Roshan D; Graham S; Lehane C; Wykes J; Campbell P; Ebrahimi A
    ANZ J Surg; 2018 Nov; 88(11):1193-1197. PubMed ID: 29701284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Feasibility Study Shows Multicenter, Observational Case-Control Study Is Practicable to Determine Risk of Secondary Breast Cancer in Females With Differentiated Thyroid Carcinoma Given Radioiodine Therapy in Their Childhood or Adolescence; Findings Also Suggest Possible Fertility Impairment in Such Patients.
    Drozd V; Schneider R; Platonova T; Panasiuk G; Leonova T; Oculevich N; Shimanskaja I; Vershenya I; Dedovich T; Mitjukova T; Grelle I; Biko J; Reiners C
    Front Endocrinol (Lausanne); 2020; 11():567385. PubMed ID: 33193085
    [No Abstract]   [Full Text] [Related]  

  • 34. Histopathological features of papillary thyroid carcinomas detected during four screening examinations of a Ukrainian-American cohort.
    Bogdanova TI; Zurnadzhy LY; Nikiforov YE; Leeman-Neill RJ; Tronko MD; Chanock S; Mabuchi K; Likhtarov IA; Kovgan LM; Drozdovitch V; Little MP; Hatch M; Zablotska LB; Shpak VM; McConnell RJ; Brenner AV
    Br J Cancer; 2015 Dec; 113(11):1556-64. PubMed ID: 26625214
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical association of CXCR4 in primary tumor of papillary thyroid cancer and response to iodine-131 treatment.
    Sirakriengkrai K; Tepmongkol S; Keelawat S; Techavijit U
    Nucl Med Commun; 2021 Apr; 42(4):396-401. PubMed ID: 33306632
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Morphological characteristics of recurrent papillary thyroid carcinoma].
    Abrosimov AIu; Ryzhenkova MI
    Arkh Patol; 2014; 76(5):13-9. PubMed ID: 25543403
    [TBL] [Abstract][Full Text] [Related]  

  • 37. De-differentiation of papillary thyroid carcinoma into squamous cell carcinoma in an elderly patient: A case report.
    Thewjitcharoen Y; Krittiyawong S; Butadej S; Nakasatien S; Polchart S; Junyangdikul P; Kanchanapituk A; Himathongkam T
    Medicine (Baltimore); 2020 Apr; 99(16):e19892. PubMed ID: 32312017
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PD-L1 and thyroid cytology: A possible diagnostic and prognostic marker.
    Dell'Aquila M; Granitto A; Martini M; Capodimonti S; Cocomazzi A; Musarra T; Fiorentino V; Pontecorvi A; Lombardi CP; Fadda G; Pantanowitz L; Larocca LM; Rossi ED
    Cancer Cytopathol; 2020 Mar; 128(3):177-189. PubMed ID: 31821747
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake.
    Lee YA; Lee H; Im SW; Song YS; Oh DY; Kang HJ; Won JK; Jung KC; Kwon D; Chung EJ; Hah JH; Paeng JC; Kim JH; Choi J; Kim OH; Oh JM; Ahn BC; Wirth LJ; Shin CH; Kim JI; Park YJ
    J Clin Invest; 2021 Sep; 131(18):. PubMed ID: 34237031
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
    Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
    Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.